As a target for stroke therapies, the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas [ACE2/Ang-(1-7)/Mas] axis of the renin-angiotensin system can be activated chronically to induce neuroprotective effects, in opposition to the deleterious effects of angiotensin II via its type 1 receptor. However, more clinically relevant treatment protocols with Ang-(1-7) that involve its systemic administration beginning after the onset of ischaemia have not been tested.
INTRODUCTION
Cerebrovascular stroke is a leading cause of worldwide death and disability, and effective therapies are urgently needed for both ischaemic and haemorrhagic forms of this disease (Donnan, Fisher, Macleod, & Davis, 2008; Mozaffarian et al., 2016; Sarikaya, Ferro, & Arnold, 2015) . The protective arm of the renin-angiotensin system, consisting of the angiotensin II-angiotensin type 2 receptor and the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor [ACE2/Ang-(1-7)/Mas] pathways, both stand as promising avenues for the development of new treatments for stroke (Peña-Silva & Heistad, 2015) . Activation of the latter pathway, the ACE2/Ang-(1-7)/Mas axis, has indeed shown therapeutic promise in both ischaemic and haemorrhagic strokes, according to studies from independent groups c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society of investigators using different models of stroke induction, as recently reviewed (Gironacci, Cerniello, Longo Carbajosa, Goldstein, & Cerrato, 2014; Regenhardt, Bennion, & Sumners, 2014) . In each of those studies, Ang-(1-7) was infused directly into the brain via the intracerebroventricular route, to circumvent the blood-brain barrier Jiang et al., 2014; Jiang et al., 2012; Lu et al., 2013; Mecca et al., 2011; Regenhardt et al., 2013; Regenhardt & Mecca, et al., 2014; Zheng, Li, Chen, Bihl et al., 2014; Zheng, Li, Chen, Wang et al., 2014) .
Furthermore, intracerebroventricular infusion of the ACE2 activator diminazine aceturate (DIZE) also elicited significant neuroprotection (Mecca et al., 2011) .
The mechanisms underlying these neuroprotective effects of the ACE2/Ang-(1-7)/Mas axis have been well studied and appear to be multiple. For example, the observed neuroprotective actions of
New Findings
• What is the central question of this study? decreases cerebral infarct volume and improves neurological function when delivered centrally before and during ischaemic stroke. Here, we assessed the neuroprotective effects of angiotensin-(1-7) when delivered orally post-stroke.
• What is the main finding and its importance?
We show that oral delivery of angiotensin-(1- 7) attenuates cerebral damage induced by middle cerebral artery occlusion in rats, without affecting blood pressure or cerebral blood flow. Importantly, these treatments begin post-stroke at times coincident with the treatment window for tissue plasminogen activator, providing supporting evidence for clinical translation of this new therapeutic strategy.
Ang-(1-7) were associated with antioxidant, anti-inflammatory and pro-angiogenic effects of this peptide (Jiang et al., 2014; Jiang et al., 2012; Regenhardt et al., 2013; Zheng, Li, Chen, Bihl, et al., 2014) . It is also possible that the neuroprotective actions of Ang-(1-7) involve a vasodilator action attributable to increased endothelial nitric oxide synthase/nitric oxide generation and consequent increases in cerebral blood flow (CBF; Zhang et al., 2008) . However, the reports on whether or not Ang-(1-7) elicits increases in CBF (Jiang et al., 2014; Mecca et al., 2011) and vasodilatory actions in cerebral vessels have provided conflicting data (Durand, Raffai, Weinberg, & Lombard, 2010; Feterik, Smith, & Katusic, 2000; Meng & Busija, 1993) ; therefore, it is not clear whether increased CBF plays a role in neuroprotection elicited by this peptide.
Despite these strong preclinical findings, which support a protective role for the ACE2/Ang-(1-7)/Mas axis in stroke, all the studies involved the application of Ang-(1-7) or an ACE2 activator before induction of stroke. To provide a more translational approach, in a recent study we administered DIZE systemically, via the intraperitoneal route, after induction of ischaemic stroke. When applied in this way, DIZE elicited a moderate but significant beneficial effect (Bennion et al., 2015) . Nonetheless, if the ACE2/Ang-(1-7)/Mas axis were to be developed further as a therapeutic avenue for stroke, it is important to assess whether other strategies for its post-stroke activation can provide improved neuroprotection. In the present experiments, we used an innovative strategy for targeting this axis by using an oral formulation, in which Ang-(1-7) is complexed with hydroxypropyl--cyclodextrins [HP CD-Ang-(1-7)], which prevents gastric degradation of this otherwise unstable peptide hormone and facilitates its delivery and absorption after cyclodextrin digestion by colon microflora (Lula et al., 2007) . Other studies have demonstrated that HP CD-Ang-(1-7) induces anti-thrombotic (Fraga-Silva et al., 2011) and cardioprotective effects (Marques et al., 2011) , and salutary effects in various other conditions (Bertagnolli et al., 2014; Sabharwal et al., 2014) . Here, we determined whether oral administration of HP CD-Ang-(1-7) in rats after ischaemic stroke would provide neuroprotection. Furthermore, we assessed whether any neuroprotective actions of this compound were associated with alterations in CBF and other cardiovascular parameters.
METHODS

Ethical approval
All experimental procedures conformed to the US National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the University of Florida Institutional Animal Care and Use Committee (#201607775). Experiments were performed and reported according to the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) . Male Sprague-Dawley rats (9 and 13 weeks old), purchased from Charles River Farms (Wilmington, MA, USA), were used. Rats were housed in well-ventilated, specific pathogen-free, temperature-controlled facilities (24 ± 1 • C; 12 h-12 h light-dark cycle) with ad libitum access to water and standard rodent chow, and underwent daily health checks.
Materials
Endothelin-1 (ET-1) was purchased from American Peptide Company, and prepared by a lyophilization process (De Sousa et al., 2008) . Unless otherwise noted, all other chemicals were purchased from Fisher Scientific (Pittsburgh, PA, USA).
Anaesthesia, analgesia and method of killing
For surgical procedures, general anaesthesia was induced using 4% isoflurane in O 2 and maintained throughout the surgeries by the administration of 2% isoflurane in O 2 . During the surgeries/procedures, the depth of anaesthesia was monitored by checking the eye blink reflex and a reaction to paw pinch, and was adjusted if necessary. This maintenance level of anaesthesia was also used during continuous recordings of CBF. Postoperative analgesia was provided using buprenorphine (0.05 mg kg −1 , S.C.; Hospira Inc., Lake Forest, IL, USA). Animals were killed by placing them under deep anaesthesia with 5% isoflurane in O 2 , followed by decapitation. ). The relative CBF was measured in the entire ischaemic region over the right hemisphere, which contains both the stroke core and the surrounding at-risk tissues. When we have previously recorded isolated reductions in CBF in the stroke core, we observed near-complete cessation of flow in comparison to the penumbral tissues, which still appear to maintain some collateral flow (Mecca et al., 2009 ). We routinely observe ∼70% reductions in regional flow from baseline CBF levels after ET-1-induced MCAO in rats using this method (see Figure 3 ).
Endothelin-1-induced middle cerebral artery occlusion and measurement of CBF
Determination of intracerebral infarct volume
Cerebral infarct size in coronal sections containing the stroke core and penumbra was assessed by post-mortem staining with 2,3,5-triphenyltetrazolium chloride (0.05%) and infarct volume determined as detailed previously (Bennion et al., 2015; Mecca et al., 2011 ).
Neurological function and paw adhesive testing
Post-stroke neurological function was assessed using a modified
Bederson scoring scale (0, no deficit; 3, maximal deficit) as described previously (Bennion et al., 2015) . Functional sensorimotor deficits
were assessed by applying a 1-cm-diameter adhesive tape to the impaired paw and measuring the latency to touch and removal by peeling the adhesive tape off of the paw. Damage to the somatosensory cortex slows or eliminates removal by impairing sensation and motor dexterity (Bouet et al., 2009) . Times >2 min were recorded as 120 s.
The average of the two best of three trials per session was recorded.
Rats underwent two training sessions pre-stroke.
Randomization and concealment of allocation
Animals were identified by an assigned number and randomized using the randomize function in Microsoft Excel. Treatment administration, data collection, infarct volume assessment, neurological assessments and data analyses were performed by investigators blinded to group allocation.
Experimental protocols 2.8.1 Experiment 1a
The neuroprotective effects of post-stroke gavages of orally active Ang-(1-7) were assessed by randomly assigning Sprague-Dawley rats (9 weeks old) to receive H 2 O (control, n = 13) or HP CD-Ang-(1-7)
(125 g kg −1 , diluted based on weight in 0.5-1 ml of H 2 O, n = 13) at 4 h, 1 and 2 days after ET-1-induced MCAO, with assessment of percentage infarct volume and neurological function as outcome measures at 3 days post-stroke. The dose of 125 g kg −1 was selected based on favourable results from our preliminary studies using this dose and a lower dose of HP CD-Ang-(1-7) (62.5 g kg −1 ). In the 24 h after ET-1-induced stroke, one animal from each group died.
The remaining animals were humanely killed and brains harvested for evaluation of infarct size at the 3 day time point.
Experiment 1b
A separate group of rats was randomized to control (n = 9) or HP CDAng-(1-7) (125 g kg −1 , n = 9) to test the effects of adding an earlier treatment gavage at 90 min post-stroke in addition the 4 h, 1 and 2 day treatments. These animals also underwent evaluation by the paw adhesive testing before stroke and again at 1 and 3 days post-stroke.
One animal in the control group died before the infarct volume analysis at 3 days post-stroke and was not included in any analyses.
Experiment 2
To test for effects of orally active Ang-(1-7) on cardiovascular function during baseline, adult Sprague-Dawley rats were implanted with telemetry recording devices (TA11PA-C40; DSI, St Paul, MN, USA)
in the abdominal aorta exactly as detailed in Bennion et al. (2018) , followed by 1 week of recovery. In a cross-over study design with 2 days washout between each treatment administration, animals (n = 8) were given a gavage of H 2 O or HP CD-Ang-(1-7) at one of two doses (125 or 250 g kg −1 ) before undergoing telemetry recordings in baseline conditions for 6 h from morning to afternoon. The higher dose (250 g kg −1 ) was selected to assess whether haemodynamic alterations could be elicited by doubling of the neuroprotective dose.
After an additional washout at the conclusion of these cross-over experiments, rats (now aged 13 weeks owing to the telemetry surgery, recovery and cross-over studies and washout described) were then randomly assigned to gavage with H 2 O (n = 4) or HP CD-Ang-(1-7)
(125 g kg −1 , n = 4). This was followed 30 min later by ET-1-induced MCAO and home cage telemetry recordings between 30 and 90 min post-stroke to test for effects of treatment on blood pressure, heart rate and activity, followed immediately by humane killing.
Experiment 3
To test for effects of orally administered HP CD-Ang-(1-7) on CBF after ET-1-induced MCAO, 9-week-old Sprague-Dawley rats were randomly assigned to two groups and anaesthetized with isoflurane as described above. Under general anaesthesia, a polyethylene gavage tube was inserted orally to the level of the stomach using a curved gavage needle as a guide. Next, the gavage needle was removed, leaving the polyethylene gavage tube in place, and the rat was placed in a Kopf stereotaxic frame with the gavage tube extending through a specially designed mouthpiece. Baseline CBF was recorded using laser Doppler flowmetry, and MCAO was induced via ET-1 injection.
After MCAO, CBF was recorded for 30 min, followed by oral gavage of either HP CD-Ang-(1-7) (125 g kg −1 , n = 12) or H 2 O (control, n = 11). Cerebral blood flow was then monitored continuously for 1 h after gavage.
Exclusions
Data from one animal in each group in Experiment 1a were excluded, because it was determined that a malfunction in the syringe for ET-1 microinjection had interfered with the induction of MCAO for these two animals. All other surviving animals were included. There were no exclusions from Experiment 2 or 3.
Data analysis
Determination of sample size was based on the primary outcome and assumed a standard deviation of 20%, effect size of 15%, power of 0.8, 
RESULTS
Cerebroprotective action of HP CD-Ang-(1-7) administered orally post-stroke
The effects of post-stroke oral administration of HP CD-Ang- (1-7) on the cerebral damage and behavioural deficits produced by ET-1-induced MCAO were tested as described in section 2.8.1 Experiment 1a.
In preliminary experiments, we tested HP CD-Ang-(1-7) at a dose of 62.5 g kg −1 (n = 9 rats), and it afforded no significant protection in terms of cerebral damage or improvement in neurological function (data not shown). However, rats receiving gavages of HP CD-Ang-(1-7) at 125 g kg −1 (n = 12) exhibited significantly smaller infarct volumes on average compared with H 2 O-treated rats (n = 12; 32.6 ± 9.5 versus 42.7 ± 17.8%, P = 0.048; Figure 1a ). 
Orally-administered HP CD-Ang-(1-7) does not alter blood pressure or heart rate during stroke
Agents that exhibit beneficial protective actions during ischaemic stroke should, ideally, not lower blood pressure (Semplicini & Calò, 2005 ). Thus, we tested the effects of orally administered F I G U R E 2 Oral administration of HP CD-Ang-(1-7) does not alter mean arterial blood pressure (MAP) or heart rate (HR) during ischaemic stroke. (a-c) Naive Sprague-Dawley rats were administered sterile water (n = 8) or HP CD-Ang-(1-7) (125 g kg −1 , n = 8; or 250 g kg −1 , n = 8) via oral gavage (grey arrows). This was followed by continuous telemetric measurement of MAP (a), HR (b) and locomotor activity (c) over the next 6 h. (d-f) Sprague-Dawley rats were administered either sterile water (n = 4) or HP CD-Ang-(1-7) (125 g kg −1 , n = 4; grey arrows) via oral gavage. Thirty minutes later, all rats underwent endothelin-1-induced occlusion of the right middle cerebral artery (black arrows), followed by continuous telemetric measurement of MAP (d), HR (e) and locomotor activity (f) over the next hour. Data are means ± SD towards baseline values, measured over the subsequent hour, when compared with the control animals (n = 7; Figure 3 ).
DISCUSSION
The significant neuroprotective actions of Ang-(1-7) had been demonstrated in multiple previous studies Jiang et al., 2014; Jiang et al., 2012; Lu et al., 2013; These findings are significant in that they demonstrate that Ang-
(1-7) can be applied orally after stroke and elicit significant neuroprotective effects, but they raise a number of questions that bear discussion. One major issue concerns the mechanism(s) of action of Ang-(1-7) in eliciting the observed protective effects. One mechanism might be to stimulate an increase in CBF and maintain flow through the damaged penumbra. However, whether or not Ang-(1-7) can alter CBF is controversial, and our data would appear to indicate that increasing CBF is not a mechanism by which orally applied HP CDAng-(1-7) affords neuroprotection ( Figure 3 ). Of note, at the levels of CBF reduction we observed, there was not a significant association between higher levels of percentage CBF reduction and percentage infarct volume in either the control or the HP CD-Ang-(1-7) group.
This might indicate that after reaching a certain threshold of flow reduction that can be observed by regional CBF recording, additional reductions do not result in larger infarcts. This is probably influenced by the limitation of regional CBF recording by laser Doppler flowmetry as an imprecise measure of the flow in the stroke core, where the most profound ischaemic damage occurs.
As it appears from our data that stimulation of CBF by Ang-(1-7) is not primarily responsible for the observed protective effects, our assumption, based upon previous work from different groups of investigators, is that Ang-(1-7) exerts its neuroprotective actions through potent antioxidant, anti-inflammatory and pro-angiogenic effects (Jiang et al., 2014; Jiang et al., 2012; Regenhardt et al., 2013; Zheng, Li, Chen, Bihl, et al., 2014) . However, for these effects to occur, Ang-(1-7) must enter the brain, and this entry into the CNS will normally be limited by the blood-brain barrier. It is likely, therefore, that orally applied Ang-(1-7) is able to exert neuroprotective effects, via the above mechanisms, by penetrating through the blood-brain barrier, which is compromised during stroke (Kassner & Merali, 2015) .
Regarding effects on cardiovascular function, our data indicate that the acute oral administration of HP CD-Ang-(1-7) after stroke (or in naive animals) does not lower blood pressure (Figure 2 ), similar to its lack of effects on blood pressure in normotensive mice (Sabharwal et al., 2014) . However, it should be noted that chronic daily treatment with HP CD-Ang-(1-7) does reduce blood pressure in the setting of hypertension (Bertagnolli et al., 2014) . The fact that HP CD-Ang-
(1-7) does not significantly decrease blood pressure after stroke is beneficial. This is because after an acute ischaemic stroke, the autoregulation of cerebral perfusion is lost in the stroke penumbra, the area that surrounds the stroke core and which dies slowly within days to weeks. As a result of this loss of autoregulation of cerebral flow, a druginduced reduction in blood pressure might reduce cerebral perfusion, extend the ischaemic area, induce further damage and worsen the disabling consequences of the initial stroke (Semplicini & Calò, 2005) .
The present findings with HP CD-Ang-(1-7) are especially relevant in light of recent evidence that serum ACE2 activity is decreased during acute ischaemic stroke in both rodents (Bennion et al., 2015) and humans (Bennion et al., 2016) and that activation of ACE2 during this period is significantly neuroprotective (Bennion et al., 2015) . Previous studies have demonstrated that oral administration of the HP CD-Ang-(1-7) inclusion complex results in increased plasma Ang-(1-7) concentrations (Fraga-Silva et al., 2011; Marques et al., 2011) . Thus, strategies resulting in the activation of Mas, whether by activation of ACE2 to generate more endogenous Ang-(1-7) or by exogenously administered Ang-(1-7), such as orally administered HP CD-Ang-(1-7), are promising avenues for inducing stroke neuroprotection.
Conclusions
The present study not only provides further evidence to support the body of literature showing that Ang-(1-7) is protective in stroke, but also it provides an important demonstration that Ang-(1-7) can exert beneficial effects when applied systemically post-stroke. The data are encouraging and indicate a potential new therapeutic avenue. Future approaches should also consider ways of delivering Ang-(1-7) to the brain that do not have to rely on degradation of the blood-brain barrier post-stroke.
